false
0001566044
0001566044
2023-11-13
2023-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
November 13, 2023
VYNE
Therapeutics Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-38356 |
|
45-3757789 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification Number) |
685
Route 202/206 N., Suite 301
Bridgewater,
New Jersey 08807
(Address of principal executive offices, including
Zip Code)
(800)
775-7936
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
Common
Stock, $0.0001 par value |
|
VYNE |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On November 13, 2023, VYNE Therapeutics Inc. issued a press release
announcing its financial results for the quarter ended September 30, 2023. The press release is being furnished as Exhibit 99.1.
The information in Item 2.02 of this Form 8-K and Exhibit 99.1
attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such
a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is being furnished herewith.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
VYNE THERAPEUTICS INC. |
|
|
|
Date: November 13, 2023 |
By: |
/s/ Mutya Harsch |
|
|
Mutya Harsch |
|
|
Chief Legal Officer and General Counsel |
Exhibit 99.1
VYNE Therapeutics Reports Third Quarter 2023
Financial Results and Provides Business Update
Transformative capital
raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025
Phase 2b preparatory activities progressing
for VYN201 in nonsegmental vitiligo following positive Phase 1b results
On track for VYN202 IND submission by year-end
2023, with plans to begin Phase 1a trial in Q1 2024
BRIDGEWATER, N.J., November 13, 2023 -- VYNE
Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused
on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced
financial results for the three and nine months ended September 30, 2023 and provided a business update.
“We have made substantial progress in advancing
our business in recent months,” said David Domzalski, President and Chief Executive Officer of VYNE. “With positive results
from our Phase 1b trial, we believe there is strong support to advance VYN201 as a potential category-leading therapy in the treatment
of vitiligo. In addition, we remain on track to submit our IND for VYN202 by the end of this year, with plans to initiate a Phase 1a single
ascending dose/multiple ascending dose trial in the first quarter of 2024. Upon successful completion of the Phase 1a trial, we plan to
initiate Phase 1b proof-of-concept trials in moderate-to-severe plaque psoriasis and in moderate-to-severe adult-onset rheumatoid arthritis
in the second half of 2024.”
“Our completion of an $88.2 million capital
raise from premier healthcare investors significantly strengthens our balance sheet and we believe highlights the enthusiasm for our InhiBET™
platform,” continued Mr. Domzalski. “By extending our cash runway through the end of 2025, we can focus on executing our
strategy of validating BET inhibition as a treatment for immuno-inflammatory conditions and delivering on key value-creating milestones.”
Recent Corporate Update
$88.2 million private placement with leading
fundamental healthcare investors, extended cash runway through the end of 2025. On November 1, 2023, the Company completed a
private placement financing (the “PIPE”) resulting in gross proceeds to the Company of $88.2 million, before deducting placement
agent fees and offering expenses, from the sale of 10,652,543 shares of common stock at a purchase price of $2.245 per share and, in lieu
of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 28,614,437 shares of common stock at a purchase
price of $2.2449 per pre-funded warrant. The net proceeds from the offering are expected to be used to fund the advancement of VYN201
into a Phase 2b clinical trial in vitiligo and Phase 1 trials for VYN202.
Recent Pipeline Updates
VYN201, a locally-administered pan-BD BET inhibitor:
| • | Positive top-line Phase 1b results in nonsegmental vitiligo. Significant
clinical improvement was observed in the 1% and 2% dosing cohorts with rapid onset of action and a dose-dependent response. The mean percentage
reduction in F-VASI (facial vitiligo scoring index) score from baseline after 16 weeks of treatment was 7.5%, 30.2% and 39.0% for the
0.5%, 1.0% and 2.0% cohorts, respectively. In addition, VYN201 was generally well-tolerated with a favorable safety profile in vitiligo
patients at all dose levels, with no serious adverse events reported and no abnormal laboratory values suggestive of low or reducing platelet
counts. VYNE has initiated Phase 2b preparatory activities and expects to advance VYN201 into a longer duration Phase 2b trial to evaluate
optimal dosing and peak efficacy in patients with active and stable nonsegmental vitiligo in the first half of 2024, with top-line results
expected in mid-2025. |
VYN202, an oral small molecule BD2-selective BET inhibitor:
| • | Psoriasis and rheumatoid arthritis selected as lead indications
with IND submission expected by year-end. Based on positive preclinical data from well-established animal models, VYNE has selected
moderate-to-severe plaque psoriasis and moderate-to-severe adult-onset rheumatoid arthritis as the lead indications for its VYN202 program.
VYNE expects to submit its IND for VYN202 by year-end 2023 and commence a first-in-human Phase 1a single ascending dose/multiple ascending
dose trial in the first quarter of 2024. Upon successful completion of the Phase 1a trial, the Company expects to initiate Phase 1b proof-of-concept
trials in these indications in the second half of 2024, with top-line results expected in mid-2025. |
Financial Performance | |
Three Months Ended September 30 | | |
Nine Months Ended September 30 | |
(in thousands) | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Loss from continuing operations (GAAP) | |
$ | (6,071 | ) | |
$ | (9,255 | ) | |
$ | (21,720 | ) | |
$ | (26,184 | ) |
Adjusted loss from continuing operations (non-GAAP)* | |
$ | (5,208 | ) | |
$ | (8,081 | ) | |
$ | (19,125 | ) | |
$ | (22,602 | ) |
Net loss (GAAP) | |
$ | (6,584 | ) | |
$ | (9,459 | ) | |
$ | (22,264 | ) | |
$ | (13,265 | ) |
Adjusted net loss (non-GAAP)* | |
$ | (5,721 | ) | |
$ | (8,285 | ) | |
$ | (19,669 | ) | |
$ | (10,035 | ) |
*See “Non-GAAP Financial Measures” elsewhere in this earnings
release.
Liquidity and Capital Resources
As of September 30, 2023, VYNE had cash and
cash equivalents and restricted cash of $15.5 million. When adding the gross proceeds received from the PIPE, VYNE’s cash and cash equivalents
and restricted cash as of September 30, 2023 would have been approximately $103.7 million. VYNE currently anticipates that its cash
and cash equivalents and restricted cash as of September 30, 2023, together with the gross proceeds from the PIPE, will be sufficient
to fund its operations through the end of 2025. See Note 1 to VYNE’s unaudited interim condensed consolidated financial statements
included in VYNE’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 for additional discussion on
liquidity and capital resources.
Financial Results for the Third Quarter Ended September 30,
2023
Revenues. Revenues for the quarter
ended September 30, 2023 totaled $0.1 million compared to $0.2 million for the quarter ended September 30, 2022, consisting
of royalty revenue.
Research and development expenses.
VYNE’s research and development expenses for the quarter ended September 30, 2023 were $3.3 million, as compared to $5.5 million
for the comparable period in 2022. The decrease was primarily driven by decreased spend for FMX114
and VYN201 and lower employee-related expenses. The decrease was partially offset by increased
spend for VYN202.
Selling, general and administrative expenses.
VYNE’s selling, general and administrative expenses for the quarter ended September 30, 2023 were $3.0 million, compared
to $4.0 million for the comparable period in 2022. The decrease was primarily driven by decreased consulting and professional fees and
lower corporate insurance expenses.
Net loss. Net loss and net loss
per share for the quarter ended September 30, 2023 was $6.6 million and $2.01, respectively, compared to a net loss and net loss
per share of $9.5 million and $2.94 for the comparable period in 2022, respectively. Net loss reported for the third quarter of 2023 reflected
the impact of $0.5 million from discontinued operations, net of income taxes. The third quarter of 2022 reflected the impact of $0.2 million
from discontinued operations, net of income taxes.
About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of
patients by developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s
unique and proprietary bromodomain & extra-terminal (BET) domain inhibitors, which comprise its InhiBET™ platform, include
a locally administered pan-BD BET inhibitor (VYN201) and an orally available BD2-selective BET inhibitor (VYN202) that were licensed from
Tay Therapeutics Limited.
For more information about VYNE Therapeutics Inc.
or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its
disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press
releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com
Cautionary Statement Regarding Forward-Looking Statements
This release includes forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding
VYNE’s plans, regulatory filings and development timelines for VYN201 and VYN202, VYNE’s InhiBET™ platform,
VYNE’s projected cash runway through the end of 2025, and other statements regarding
the future expectations, plans and prospects of VYNE. All statements in this press release which are not historical facts are forward-looking
statements. Any forward-looking statements are based on VYNE’s current knowledge and its present beliefs and expectations regarding
possible future events and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially and
adversely from those set forth or implied by such forward-looking statements. These risks and uncertainties include, but are not limited
to: VYNE’s ability to successfully develop its product candidates; the timing of the commencement of future non-clinical studies
and clinical trials; VYNE’s ability to enroll patients and successfully progress, complete, and receive favorable results in clinical
trials for its product candidates; VYNE’s ability to comply with various regulations applicable to its business; VYNE’s ability
to create intellectual property and the scope of protection it is able to establish and maintain for intellectual property rights covering
its product candidates, including the projected terms of patent protection; risks that any of VYNE’s patents may be held to be narrowed,
invalid or unenforceable or one or more of VYNE’s patent applications may not be granted and potential competitors may also seek
to design around VYNE’s granted patents or patent applications; estimates of VYNE’s expenses, capital requirements, its needs
for additional financing and its ability to obtain additional capital on acceptable terms or at all; VYNE’s expectations regarding
licensing, business transactions and strategic operations; VYNE’s future financial performance and liquidity; and potential volatility
in VYNE’s stock price that may result in rapid and substantial increases or decreases in the stock price that may or may not be
related to VYNE’s operating performance or prospects. For a discussion of other risks and uncertainties, and other important factors,
any of which could cause VYNE’s actual results to differ from those contained in the forward-looking statements, see the section
titled “Risk Factors” in VYNE’s Annual Report on Form 10-K for the year ended December 31, 2022, VYNE’s
Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, as well as discussions of potential risks, uncertainties,
and other important factors in VYNE’s subsequent filings with the U.S. Securities and Exchange Commission. Although VYNE believes
these forward-looking statements are reasonable, they speak only as of the date of this announcement and VYNE undertakes no obligation
to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Given these risks and uncertainties, you should not rely upon forward-looking statements as predictions of future events.
VYNE THERAPEUTICS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands, except share and per
share data)
(Unaudited)
| |
September 30 | | |
December 31 | |
| |
2023 | | |
2022 | |
Assets | |
| | | |
| | |
Current Assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 15,448 | | |
$ | 30,908 | |
Restricted cash | |
| 54 | | |
| 67 | |
Trade receivables, net of allowances | |
| 250 | | |
| 173 | |
Amount due from sale of MST Franchise | |
| — | | |
| 5,000 | |
Prepaid and other expenses | |
| 1,759 | | |
| 2,127 | |
Total Current Assets | |
| 17,511 | | |
| 38,275 | |
Non-current prepaid expenses and other assets | |
| 1,756 | | |
| 2,483 | |
Total Assets | |
$ | 19,267 | | |
$ | 40,758 | |
| |
| | | |
| | |
Liabilities, Mezzanine Equity and Stockholders’ Equity | |
| | | |
| | |
Current Liabilities: | |
| | | |
| | |
Trade payables | |
$ | 716 | | |
$ | 2,386 | |
Accrued expenses | |
| 4,452 | | |
| 4,381 | |
Employee related obligations | |
| 1,281 | | |
| 2,372 | |
Liability for employee severance benefits | |
| — | | |
| 206 | |
Total Current Liabilities | |
| 6,449 | | |
| 9,345 | |
Other liabilities | |
| 1,313 | | |
| — | |
Total Liabilities | |
| 7,762 | | |
| 9,345 | |
| |
| | | |
| | |
Commitments and Contingencies | |
| | | |
| | |
| |
| | | |
| | |
Mezzanine Equity: | |
| | | |
| | |
Convertible Preferred Stock: $0.0001 par value; 20,000,000 shares authorized at September 30, 2023 and December 31, 2022; Series A Preferred Stock: 0 and 3,000 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | |
| — | | |
| 211 | |
| |
| | | |
| | |
Stockholders’ Equity: | |
| | | |
| | |
Common stock: $0.0001 par value; 150,000,000 shares authorized at September 30, 2023 and December 31, 2022; 3,304,781 and 3,229,704 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | |
| — | | |
| — | |
Additional paid-in capital | |
| 696,653 | | |
| 693,937 | |
Accumulated deficit | |
| (685,148 | ) | |
| (662,735 | ) |
Total Stockholders’ Equity | |
| 11,505 | | |
| 31,202 | |
Total Liabilities, Mezzanine Equity and Stockholders’ Equity | |
$ | 19,267 | | |
$ | 40,758 | |
VYNE THERAPEUTICS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except per share data)
(Unaudited)
| |
Three Months Ended September
30 | | |
Nine Months Ended September
30 | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenues | |
| | | |
| | | |
| | | |
| | |
Royalty revenues | |
$ | 114 | | |
$ | 167 | | |
$ | 348 | | |
$ | 471 | |
Total revenues | |
| 114 | | |
| 167 | | |
| 348 | | |
| 471 | |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development | |
| 3,318 | | |
| 5,546 | | |
| 13,284 | | |
| 14,106 | |
Selling, general and administrative | |
| 3,030 | | |
| 3,954 | | |
| 9,490 | | |
| 12,676 | |
Total operating expenses | |
| 6,348 | | |
| 9,500 | | |
| 22,774 | | |
| 26,782 | |
Operating loss | |
| (6,234 | ) | |
| (9,333 | ) | |
| (22,426 | ) | |
| (26,311 | ) |
Other income, net | |
| 163 | | |
| 78 | | |
| 706 | | |
| 127 | |
Loss from continuing operations before income taxes | |
| (6,071 | ) | |
| (9,255 | ) | |
| (21,720 | ) | |
| (26,184 | ) |
Income tax expense | |
| — | | |
| — | | |
| — | | |
| — | |
Loss from continuing operations | |
| (6,071 | ) | |
$ | (9,255 | ) | |
| (21,720 | ) | |
| (26,184 | ) |
(Loss) income from discontinued operations, net of income taxes | |
| (513 | ) | |
| (204 | ) | |
| (544 | ) | |
| 12,919 | |
Net loss | |
$ | (6,584 | ) | |
$ | (9,459 | ) | |
$ | (22,264 | ) | |
$ | (13,265 | ) |
| |
| | | |
| | | |
| | | |
| | |
Loss per share from continuing operations, basic and diluted | |
$ | (1.85 | ) | |
$ | (2.88 | ) | |
$ | (6.66 | ) | |
$ | (8.25 | ) |
(Loss) income per share from discontinued operations, basic and diluted | |
$ | (0.16 | ) | |
$ | (0.06 | ) | |
$ | (0.17 | ) | |
$ | 4.07 | |
Loss per share, basic and diluted | |
$ | (2.01 | ) | |
$ | (2.94 | ) | |
$ | (6.82 | ) | |
$ | (4.18 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average shares outstanding - basic and diluted | |
| 3,282 | | |
| 3,218 | | |
| 3,271 | | |
| 3,173 | |
Non-GAAP Financial Measures
In evaluating the operating performance of its
business, VYNE’s management considers adjusted net loss, adjusted net loss per share, adjusted loss from continuing operations,
adjusted total operating expenses (including adjusted research and development expense and adjusted selling, general and administrative
expense), adjusted operating loss and adjusted loss per share from continuing operations. These non-GAAP financial measures exclude stock-based
compensation charges that are required by GAAP. The Company believes that these non-GAAP financial measures provide management,
analysts, investors and other users of the Company’s financial information with meaningful supplemental information regarding the
performance of the Company’s business by excluding the effect of certain non-cash expenses and items that VYNE believes may not
be indicative of its operating performance, because they are either unusual and VYNE does not expect them to recur in the ordinary course
of its business, or they are unrelated to the ongoing operation of the business in the ordinary course. These non-GAAP financial measures
should not be considered superior to, but rather in addition to, other financial measures prepared by the Company in accordance with GAAP,
including the period-to-period results. The Company’s method of determining these non-GAAP financial measures may be different from
other companies’ methods and, therefore, may not be comparable to those used by other companies, and the Company does not recommend
the sole use of these non-GAAP measures to assess its financial and earnings performance. For reasons noted above, the Company is presenting
certain non-GAAP financial measures for the three and nine months ended September 30, 2023 and 2022. The following tables reconcile
non-GAAP financial measures presented in this press release.
The following tables provides detailed reconciliations of various other
income statement data between GAAP and non-GAAP amounts for the three and nine months ended September 30, 2023 and 2022 (in thousands,
except per share data):
Reconciliation of net loss to adjusted net loss and net loss per
share to adjusted net loss per share:
| |
Three Months Ended September
30 | | |
Nine Months Ended September
30 | |
(in thousands, except per share data) | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Net loss (GAAP) | |
$ | (6,584 | ) | |
$ | (9,459 | ) | |
$ | (22,264 | ) | |
$ | (13,265 | ) |
Add-back: stock-based compensation expense | |
| 863 | | |
| 1,174 | | |
| 2,595 | | |
| 3,230 | |
Adjusted net loss (non-GAAP) | |
$ | (5,721 | ) | |
$ | (8,285 | ) | |
$ | (19,669 | ) | |
$ | (10,035 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss per share, basic and diluted (GAAP) | |
$ | (2.01 | ) | |
$ | (2.94 | ) | |
$ | (6.82 | ) | |
$ | (4.18 | ) |
Add-back: stock-based compensation expense | |
| 0.26 | | |
| 0.36 | | |
| 0.79 | | |
| 1.02 | |
Adjusted net loss per share, basic and diluted (non-GAAP) | |
$ | (1.75 | ) | |
$ | (2.58 | ) | |
$ | (6.03 | ) | |
$ | (3.16 | ) |
Weighted average number of shares outstanding, basic and diluted | |
| 3,282 | | |
| 3,218 | | |
| 3,271 | | |
| 3,173 | |
Reconciliation of loss from continuing operations to adjusted loss
from continuing operations; research and development expense to adjusted research and development expense; selling, general and administrative
expense to adjusted selling, general and administrative expense; total operating expenses to adjusted total operating expenses; operating
loss to adjusted operating loss; and loss per share from continuing operations to adjusted loss per share from continuing operations:
| |
Three Months Ended September 30 | | |
Nine Months Ended September 30 | |
(in thousands, except per share data) | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Loss from continuing operations (GAAP) | |
$ | (6,071 | ) | |
$ | (9,255 | ) | |
$ | (21,720 | ) | |
$ | (26,184 | ) |
Add-back: stock-based compensation expense | |
| 863 | | |
| 1,174 | | |
| 2,595 | | |
| 3,582 | |
Adjusted loss from continuing operations (non-GAAP) | |
$ | (5,208 | ) | |
$ | (8,081 | ) | |
$ | (19,125 | ) | |
$ | (22,602 | ) |
| |
| | | |
| | | |
| | | |
| | |
Research and development expense (GAAP) | |
$ | 3,318 | | |
$ | 5,546 | | |
$ | 13,284 | | |
$ | 14,106 | |
Less: stock-based compensation expense | |
| (207 | ) | |
| (355 | ) | |
| (399 | ) | |
| (977 | ) |
Adjusted research and development expense (non-GAAP) | |
$ | 3,111 | | |
$ | 5,191 | | |
$ | 12,885 | | |
$ | 13,129 | |
| |
| | | |
| | | |
| | | |
| | |
Selling, general and administrative expense (GAAP) | |
$ | 3,030 | | |
$ | 3,954 | | |
$ | 9,490 | | |
$ | 12,676 | |
Less: stock-based compensation expense | |
| (656 | ) | |
| (819 | ) | |
| (2,196 | ) | |
| (2,605 | ) |
Adjusted selling, general and administrative expense (non-GAAP) | |
$ | 2,374 | | |
$ | 3,135 | | |
$ | 7,294 | | |
$ | 10,071 | |
| |
| | | |
| | | |
| | | |
| | |
Total operating expenses (GAAP) | |
$ | 6,348 | | |
$ | 9,500 | | |
$ | 22,774 | | |
$ | 26,782 | |
Less: stock-based compensation expense | |
| (863 | ) | |
| (1,174 | ) | |
| (2,595 | ) | |
| (3,582 | ) |
Adjusted total operating expenses (non-GAAP) | |
$ | 5,485 | | |
$ | 8,326 | | |
$ | 20,179 | | |
$ | 23,200 | |
| |
| | | |
| | | |
| | | |
| | |
Operating loss (GAAP) | |
$ | (6,234 | ) | |
$ | (9,333 | ) | |
$ | (22,426 | ) | |
$ | (26,311 | ) |
Add back: stock-based compensation expense | |
| 863 | | |
| 1,174 | | |
| 2,595 | | |
| 3,582 | |
Adjusted operating loss (non-GAAP) | |
$ | (5,371 | ) | |
$ | (8,159 | ) | |
$ | (19,831 | ) | |
$ | (22,729 | ) |
| |
| | | |
| | | |
| | | |
| | |
Loss per share from continuing operations, basic and diluted (GAAP) | |
$ | (1.85 | ) | |
$ | (2.88 | ) | |
$ | (6.66 | ) | |
$ | (8.25 | ) |
Add back: stock-based compensation expense | |
| 0.26 | | |
| 0.36 | | |
| 0.79 | | |
| 1.13 | |
Adjusted loss per share from continuing operations, basic and diluted (non-GAAP) | |
$ | (1.59 | ) | |
$ | (2.52 | ) | |
$ | (5.87 | ) | |
$ | (7.12 | ) |
Weighted average number of shares outstanding - basic and diluted | |
| 3,282 | | |
| 3,218 | | |
| 3,271 | | |
| 3,173 | |
v3.23.3
Cover
|
Nov. 13, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Nov. 13, 2023
|
Entity File Number |
001-38356
|
Entity Registrant Name |
VYNE
Therapeutics Inc.
|
Entity Central Index Key |
0001566044
|
Entity Tax Identification Number |
45-3757789
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
685
Route 202/206 N.
|
Entity Address, Address Line Two |
Suite 301
|
Entity Address, City or Town |
Bridgewater,
|
Entity Address, State or Province |
NJ
|
Entity Address, Postal Zip Code |
08807
|
City Area Code |
800
|
Local Phone Number |
775-7936
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, $0.0001 par value
|
Trading Symbol |
VYNE
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
true
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
VYNE Therapeutics (NASDAQ:VYNE)
Historical Stock Chart
From Apr 2024 to May 2024
VYNE Therapeutics (NASDAQ:VYNE)
Historical Stock Chart
From May 2023 to May 2024